RxSight Q1 revenue $17.5M (+96% YoY); raises FY2023 revenue and margin guidance

RxSight, Inc.

2023-Q1 EPS reported -$0.42 revenue$17,489,000

Revenue $17.5M, up 96% YoY; gross margin improved to 59% from 42%.
Net loss $(13.2)M ($0.42/share) vs $(17.6)M loss a year ago; adjusted loss $(0.31)/share.
LAL procedure volumes 10,523 (+153% YoY); LDD installed base grew to 456 units (+85% YoY).
Raised ~$64.5M net proceeds from equity offerings; cash & investments $153.9M.
FY2023 guidance raised: revenue $79-84M (prior $78-83M); gross margin 56-58% (prior 52-54%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).

Period: first quarter 2023
Revenue: 17.5 million
Net income: (13.2) million
EPS: (0.42)
Result: reported results

Exact text from the filing

In the first quarter of 2023, total revenue was $17.5 million, an increase of 96% compared to $8.9 million in the first quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).

Period: first quarter 2023
Revenue: 17.5 million
Net income: (13.2) million
EPS: (0.42)
Result: reported results

Exact text from the filing

following cataract surgery, today reported financial results for the three months ended March 31, 2023. Key Quarterly Highlights • Reported first quarter 2023 revenue of $17.5 million, an increase of 96% compared to the first quarter of 2022, reflecting: • The sale of 56 Light Delivery Devices (LDDTMs), representing a 40% increase in unit sales compared to the

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.